Knights of Columbus Asset Advisors LLC Has $1.45 Million Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Knights of Columbus Asset Advisors LLC grew its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 82.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,695 shares of the biopharmaceutical company's stock after purchasing an additional 2,116 shares during the period. Knights of Columbus Asset Advisors LLC's holdings in Madrigal Pharmaceuticals were worth $1,449,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Paulson & CO. Inc. grew its position in shares of Madrigal Pharmaceuticals by 10.4% during the third quarter. Paulson & CO. Inc. now owns 2,042,000 shares of the biopharmaceutical company's stock worth $433,353,000 after acquiring an additional 192,000 shares during the last quarter. RTW Investments LP raised its stake in Madrigal Pharmaceuticals by 4.1% during the 3rd quarter. RTW Investments LP now owns 1,993,687 shares of the biopharmaceutical company's stock valued at $423,100,000 after acquiring an additional 77,825 shares in the last quarter. State Street Corp raised its stake in shares of Madrigal Pharmaceuticals by 19.2% during the third quarter. State Street Corp now owns 887,752 shares of the biopharmaceutical company's stock valued at $188,399,000 after purchasing an additional 143,038 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Madrigal Pharmaceuticals by 1.5% during the 3rd quarter. Geode Capital Management LLC now owns 405,655 shares of the biopharmaceutical company's stock worth $86,104,000 after buying an additional 5,801 shares in the last quarter. Finally, William Blair Investment Management LLC bought a new stake in Madrigal Pharmaceuticals during the fourth quarter worth approximately $114,717,000. Hedge funds and other institutional investors own 98.50% of the company's stock.

Remove Ads

Analyst Ratings Changes

A number of brokerages have issued reports on MDGL. B. Riley raised Madrigal Pharmaceuticals from a "hold" rating to a "strong-buy" rating and increased their price target for the company from $236.00 to $422.00 in a research note on Thursday, February 27th. HC Wainwright raised their target price on Madrigal Pharmaceuticals from $400.00 to $405.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. Citigroup lifted their target price on Madrigal Pharmaceuticals from $378.00 to $469.00 and gave the stock a "buy" rating in a report on Thursday, February 27th. Finally, JMP Securities reissued a "market outperform" rating and issued a $427.00 price target on shares of Madrigal Pharmaceuticals in a report on Friday, January 10th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Madrigal Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $378.44.

Insider Activity at Madrigal Pharmaceuticals

In other Madrigal Pharmaceuticals news, VP Robert E. Waltermire sold 14,113 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $341.32, for a total value of $4,817,049.16. Following the completion of the sale, the vice president now owns 3,728 shares in the company, valued at $1,272,440.96. This represents a 79.10 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO William John Sibold sold 1,584 shares of Madrigal Pharmaceuticals stock in a transaction on Friday, January 24th. The shares were sold at an average price of $335.24, for a total transaction of $531,020.16. Following the sale, the chief executive officer now directly owns 54,303 shares of the company's stock, valued at $18,204,537.72. This trade represents a 2.83 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 35,900 shares of company stock valued at $12,168,079. Company insiders own 22.80% of the company's stock.

Madrigal Pharmaceuticals Trading Down 0.9 %

MDGL stock traded down $3.11 during mid-day trading on Tuesday, reaching $343.29. 208,558 shares of the stock traded hands, compared to its average volume of 387,769. Madrigal Pharmaceuticals, Inc. has a 52-week low of $189.00 and a 52-week high of $377.46. The stock's fifty day moving average is $328.38 and its 200-day moving average is $294.82. The company has a market cap of $7.58 billion, a P/E ratio of -13.69 and a beta of -0.41. The company has a current ratio of 5.98, a quick ratio of 5.93 and a debt-to-equity ratio of 0.15.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($2.71) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($4.32) by $1.61. The firm had revenue of $103.32 million for the quarter, compared to analyst estimates of $97.81 million. As a group, sell-side analysts expect that Madrigal Pharmaceuticals, Inc. will post -23.47 earnings per share for the current year.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.